Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 17

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 17
---
 that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors. |
| Risk factors                                  | See "Risk Factors" and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                               |

Except as otherwise noted, all information contained in this prospectus assumes no exercise of our outstanding options (as described herein) or Warrants. The number of common shares that will be outstanding after this offering is based on 20,218,104 common shares outstanding as of August 31, 2025.

<div align='center'>7

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this prospectus

We have derived the selected condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024 and the selected consolidated balance sheet information as of June 30, 2025 and December 31, 2024 from our interim unaudited consolidated financial statements and audited consolidated financial statements, respectively, included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance with GAAP and our consolidated financial statements are presented in U.S. dollars, except where indicated otherwise. Our historical results are not necessarily indicative of the results that should be expected in any future period.

<div align='center'>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</div>

| Operating expenses:                                                        |   | Three months ended June 30, 
                        2025 |   |   |       2024 |   |   | Six months ended June 30, 
                      2025 |   |     |       2024 |   |
|:---------------------------------------------------------------------------|:--|----------------------------:|:--|:--|-----------:|:--|:--|--------------------------:|:--|:----|-----------:|:--|
| General and administrative                                                 | $ |                   4,576,524 |   | $ |  2,276,676